Holen Sie sich die Stockscreener-App
30.37
5.46%
1.59
Handel nachbörslich:
29.45
-0.92
-3.03%
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan
(APLS) Technical Data - Stock Traders Daily
KBC Group NV Has $3.33 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Cedric Francois Sells 2,824 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Sippican Capital Advisors Sells 9,560 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Morgan Stanley's Strategic Acquisition of Apellis Pharmaceuticals Shares - GuruFocus.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 546 Shares - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $24,354.00 in Stock - MarketBeat
Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Decreases By 16.0% - MarketBeat
Apellis Pharmaceuticals' (APLS) Sector Perform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $20,516.40 in Stock - MarketBeat
Apellis Pharmaceuticals chief development officer sells $8,207 in stock - MSN
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 - MSN
Apellis Pharmaceuticals chief development officer sells $8,207 in stock By Investing.com - Investing.com Canada
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals general counsel sells $20,518 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 By Investing.com - Investing.com Australia
Apellis Pharmaceuticals CFO sells $16,119 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals general counsel sells $20,518 in stock - Investing.com
Sector Update: Health Care -January 28, 2025 at 08:57 am EST - Marketscreener.com
Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA) - Marketscreener.com
Australia approves SYFOVRE as first GA treatment - MSN
Apellis Pharmaceuticals' Geographic Atrophy Treatment Gets Approval From Australian Therapeutic Goods Administration - Marketscreener.com
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA) - The Manila Times
Apellis' SYFOVRE Makes History as First-Ever Geographic Atrophy Treatment in Australia - StockTitan
Apellis Pharmaceuticals CEO Francois sells $412,295 in stock - MSN
Wedbush Predicts Higher Earnings for Apellis Pharmaceuticals - MarketBeat
What is Wedbush’s Forecast for APLS FY2024 Earnings? - Defense World
Merit Financial Group LLC Purchases New Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Apellis Pharmaceuticals VP sells $21,420 in stock - MSN
Have Apellis Pharmaceuticals Insiders Been Selling Stock? - Simply Wall St
Apellis Pharmaceuticals chief scientific officer sells shares worth $120,119 By Investing.com - Investing.com Australia
Apellis Pharmaceuticals' chief people officer sells $53,275 in stock - MSN
Apellis Pharmaceuticals CTO Nicholson Nur sells $120,119 in stock - MSN
Assenagon Asset Management S.A. Sells 2,114,422 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):